A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : FCZ / fluconazole

[Related PubMed/MEDLINE]
Total Number of Papers: 105
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   FCZ  (>> Co-occurring Abbreviation)
Long Form:   fluconazole
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 African ST173 Cryptococcus deuterogattii strains are commonly less susceptible to fluconazole: An unclear mechanism of resistance. MICs
2020 Antifungal susceptibility of oral isolates of Candida species from chronic kidney disease patients on chronic dialysis. MCZ, NYS, VCZ
2020 Cationic Ru(II) cyclopentadienyl complexes with antifungal activity against severalCandidaspecies. ROS
2020 Cinnamyl Schiff bases: synthesis, cytotoxic effects and antifungal activity of clinical interest. MIC
2020 Coumaric acid analogues inhibit growth and melanin biosynthesis in Cryptococcus neoformans and potentialize amphotericin B antifungal activity. AmB
2020 In vitro and in vivo evaluation of cubosomal nanoparticles as an ocular delivery system for fluconazole in treatment of keratomycosis. ---
2020 Prevalence and antifungal susceptibility of Candida albicans causing vaginal discharge among pregnant women in Lebanon. AmB, ICZ, VCZ
2019 In vitro activity of diphenyl diselenide and ebselen alone and in combination with antifungal agents against Trichosporon asahii. AmB, CAS, DPDS, EBS, FS, ITZ, MIC
2019 Non-Toxic and Ultra-Small Biosilver Nanoclusters Trigger Apoptotic Cell Death in Fluconazole-Resistant Candida albicans via Ras Signaling. ---
10  2019 UPLC-MS-ESI-QTOF Analysis and Antifungal Activity of the Spondias tuberosa Arruda Leaf and Root Hydroalcoholic Extracts. CA, CT, IC50, MFCs, UPLC-MS-ESI-QTOF
11  2018 Emergence of non-Candida albicans species: Epidemiology, phylogeny and fluconazole susceptibility profile. NCA
12  2018 Paeoniflorin augments systemic Candida albicans infection through inhibiting Th1 and Th17 cell expression in a mouse model. C. albicans, IFN-gamma, IL, PF, TNF-alpha
13  2018 Short Communication - Synthesis of drug metal complexes and their influence on human platelet aggregation. PZ
14  2017 An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples. CSF, ISZ, ITZ, OH-ITZ, PSZ, VRZ
15  2017 Antifungal Activity of the Ethanol Extract from Flos Rosae Chinensis with Activity against Fluconazole-Resistant Clinical Candida. FRC, MIC
16  2017 Frequency of Cutaneous Fungal Infections and Azole Resistance of the Isolates in Patients with Diabetes Mellitus. MIC
17  2017 Interactions of a prenylated flavonoid from Dalea elegans with fluconazole against azole- resistant Candida albicans. FIC, FICI, LD50, MFC
18  2016 Candida parapsilosis keratitis treated successfully with topical and oral fluconazole. ---
19  2016 Epidemiology of candidemia in neonatal intensive care units: a persistent public health problem. AmB, NICUs
20  2016 Evaluation of antifungal combination against Cryptococcus spp. 5-FC, ITZ, TRB, VRZ
21  2016 In Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen. AmB, CASP, CLSI, ITZ, KTZ, VCZ
22  2016 Quercetin Assists Fluconazole to Inhibit Biofilm Formations of Fluconazole-Resistant Candida Albicans in In Vitro and In Vivo Antifungal Managements of Vulvovaginal Candidiasis. CSH, QCT, VVC
23  2016 The prevalence of Candida onychomycosis in Southeastern Serbia from 2011 to 2015. C. albicans, ITZ
24  2016 Time-of-flight mass spectrometry assessment of fluconazole and climbazole UV and UV/H2O2 degradability: Kinetics study and transformation products elucidation. CBZ, LC-QTOF-MS, TPs
25  2015 Antifungal activity of chitooligosaccharides against the dermatophyte Trichophyton rubrum. COS, MIC
26  2015 Arteether resistance reversal by ketoconazole/fluconazole in rodent malaria parasite Plasmodium vinckei. ACT, AEI, ART, KTZ
27  2015 Does the Anesthetic Urethane Influence the Pharmacokinetics of Antifungal Drugs? A Population Pharmacokinetic Investigation in Rats. PK, VRC
28  2015 Quercetin sensitizes fluconazole-resistant candida albicans to induce apoptotic cell death by modulating quorum sensing. QC, QC, QS
29  2014 Antifungal susceptibility of Malassezia furfur, Malassezia sympodialis, and Malassezia globosa to azole drugs and amphotericin B evaluated using a broth microdilution method. AmB, ITZ, KTZ, MCZ, MICs, VCZ
30  2014 [Evaluation of the VITEK 2 system (AST-YSO1 cards) for antifungal susceptibility testing against different Candida species]. CA, CLSI, EA, VCZ
31  2013 Effect of prophylactic fluconazole on oral mucositis and candidiasis during radiation therapy for head-and-neck cancer. CRT, RT
32  2012 Comparison of fluconazole renal penetration levels in healthy and Candida albicans-infected Wistar rats. i.v
33  2012 Inhibitory effect of Shikonin on Candida albicans growth. NAC, NADPH, ROS, SK
34  2012 Susceptibility of Dermatophytes to Thiabendazole Using CLSI Broth Macrodilution. CLSI, TBZ
35  2011 Disturbance in hemoglobin metabolism and in vivo antimalarial activity of azole antimycotics. CTZ, IssHS, KTZ
36  2011 In Vitro and In Vivo Activities of Essential Oil from the Seed of Anethum graveolens L. against Candida spp. CLSI, MIC
37  2011 In vitro susceptibility of a large collection of Candida Strains against fluconazole and voriconazole by using the CLSI disk diffusion assay. DDS
38  2011 The comparison of solitary topical micafungin or fluconazole application in the treatment of Candida fungal keratitis. BCVA, MCFG
39  2010 Prior colonisation with Candida species fails to guide empirical therapy for candidaemia in critically ill adults. ICU/HDU
40  2010 Synthesis, molecular docking, and biological evaluation of novel triazole derivatives as antifungal agents. A.fum, MICs
41  2010 [Neonatal Candida infections and the antifungal susceptibilities of the related Candida species]. AmB, CSF
42  2009 Ascorbic acid decreases the antifungal effect of fluconazole in the treatment of candidiasis. AA, i.g, NAC
43  2009 Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy. AmB, HAART
44  2009 In vitro activity of antifungal drugs against Cladophialophora species associated with human chromoblastomycosis. AmB, ITZ, TBF, VCZ
45  2009 Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. AUC, CLR, GMR, HIV, RFB
46  2008 In vitro activity of Penicillium chrysogenum antifungal protein (PAF) and its combination with fluconazole against different dermatophytes. PAF
47  2007 Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in Sao Paulo, Brazil, 1995-2003. ITZ, VCZ
48  2007 Comparison of tablet and disk diffusion methods for fluconazole and voriconazole in vitro activity testing against clinical yeast isolates. VCZ
49  2007 Fluconazol method validation by RP-HPLC for determination in biological skin matrices. ---
50  2006 Change of the blood concentration of tacrolimus after the switch from fluconazole to voriconazole in patients receiving allogeneic hematopoietic stem cell transplantation. VCZ
51  2006 Fluconazole and itraconazole resistance of yeasts isolated from the bloodstream and catheters of hospitalized pediatric patients. ITZ
52  2006 In vitro effects of Ag+ on planktonic and adhered cells of fluconazole-resistant and susceptible strains of Candida albicans, C. glabrata and C. krusei. MES
53  2006 Mucosal permeability of water-soluble drugs in the equine jejunum: a preliminary investigation. BCS, CPX, IVIVC, MAR, MTZ
54  2006 Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia. TdP
55  2006 [Caspofungin: mode of action and therapeutic applications]. CAS
56  2005 [Analysis of ERG11 gene mutation in Candida albicans]. ---
57  2004 Adherence of Candida albicans to silicone induces immediate enhanced tolerance to fluconazole. ---
58  2004 Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents. 5-FC, AmB, ITZ, KCZ, MIC, TBF
59  2003 Additional investigation on the potentiation of phenytoin teratogenicity by fluconazole. PHT
60  2003 Interlaboratory evaluation of the Etest for antifungal susceptibility testing of dermatophytes. AmB, ITZ, KTZ
61  2003 Synergistic antifungal effect of fluconazole and human polymorphonuclear leukocytes on Paracoccidioides brasiliensis: effect of interferon-gamma and granulocyte-macrophage colony-stimulating factor. GM-CSF, IFN-gamma, Pb, PMN
62  2002 Efficacy of ravuconazole in treatment of systemic murine histoplasmosis. ITZ, RCZ
63  2002 In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. AB, FIC
64  2002 [Pharmacokinetics of topically applied fluconazole in the rabbit eye]. HPLC
65  2001 CaALK8, an alkane assimilating cytochrome P450, confers multidrug resistance when expressed in a hypersensitive strain of Candida albicans. CYH, NQO, PHE
66  2000 Comparative efficacies of terbinafine and fluconazole in treatment of experimental coccidioidal meningitis in a rabbit model. CSF, TBF
67  2000 Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis. CSF, ITZ
68  2000 In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy. AmB, RIF, TKC
69  2000 Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats. AUC, KCZ, NVP
70  2000 [Pharmacokinetics of topically applied in-situ-forming gels of fluconazole in rabbit eyes]. AUC
71  1999 A new azole derivative of 1,4-benzothiazine increases the antifungal mechanisms of natural effector cells. ---
72  1999 Antifungal action of Hevea brasiliensis latex. Its effect in combination with fluconazole on Candida albicans growth. ---
73  1999 Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections. AmB, ITZ
74  1999 Isolation of a putative Candida albicans transcriptional regulator involved in pleiotropic drug resistance by functional complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiae. ---
75  1999 Resistant mechanisms of Candida albicans to fluconazole. PCR, RFLP, SSCP
76  1999 Teratological interaction between the bis-triazole antifungal agent fluconazole and the anticonvulsant drug phenytoin. PHT
77  1999 The bZip transcription factor Cap1p is involved in multidrug resistance and oxidative stress response in Candida albicans. CAP1, MF
78  1999 [In vitro sensitivity of Paracoccidioides brasiliensis to systemically used antifungal agents]. AmB, ITZ, KTZ
79  1998 Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. G-CSF, GM, PMN, VCZ
80  1998 Damage to yeast cells of Cryptococcus neoformans by voriconazole and fluconazole: a culture and microscopic study. CFU, VCZ
81  1998 Effect of granulocyte-macrophage colony-stimulating factor on candidacidal activity of neutrophils, monocytes or monocyte-derived macrophages and synergy with fluconazole. GM-CSF, MDM
82  1998 Fungal peritonitis in pediatric patients. amp B, FP, i.p, PD
83  1998 [Chronic necrotizing pulmonary aspergillosis resistant to antimycotic drugs and treated by partial pulmonary resection]. ---
84  1997 AP1-mediated multidrug resistance in Saccharomyces cerevisiae requires FLR1 encoding a transporter of the major facilitator superfamily. 4NQO, CYH
85  1997 [Multisite evaluation of a colorimetric broth microdilution antifungal susceptibility testing]. AMPH, ITZ, MCZ, NCCLS
86  1996 Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model. ITZ
87  1996 Fluconazole increases bactericidal activity of neutrophils through non--cytokine-mediated pathway. IL, PMNs
88  1996 Fluconazole increases bactericidal activity of neutrophils. PMN
89  1996 Quantitative screening for fluconazole-amphotericin B antagonism in several Candida albicans strains by a comparative agar diffusion assay. AmB
90  1996 Successful treatment of fungus ball in a patient with allergic bronchopulmonary aspergillosis: continuous percutaneous instillation of antifungal agents into the cavity. ABPA, AMPH
91  1996 Synergy of human neutrophils with fluconazole in killing Candida species. CFU, P/S, TM
92  1996 [Colorimetric broth microdilution for antifungal susceptibility testing]. AMPH, MACRO, MICRO, NCCLS
93  1996 [Studies on microtiter broth dilution method for antifungal susceptibility testing of yeast isolates from blood and cerebrospinal fluid]. AMPH, MCZ, QC
94  1995 Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole. ---
95  1995 Fluconazole- and itraconazole-resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities. ETs, I to V, ITZ
96  1995 Macrophage colony-stimulating factor (M-CSF) induction of enhanced anticryptococcal activity in human monocyte-derived macrophages: synergy with fluconazole for killing. Cn, HMM, M-CSF
97  1995 Post-antibiotic effect and post-expositional polyene antagonism of azole antifungal agents in Candida albicans: dependence on substance lipophilia. ICZ, KCZ, MCZ
98  1995 Synergy of fluconazole with macrophages for antifungal activity against Candida albicans. FBS, MP
99  1995 [In vitro sensitivity tests for yeasts: evaluation of a micromethod]. AmB, ITZ, KTZ, MCZ, MIC, NCCLS
100  1995 [Post-antibiotic effect and post-exposure polyene antagonism of azole antimycotics in Candida albicans: dependency on lipophilia]. ICZ, KCZ, MCZ